Key Points Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the intention of raising them in the future. Ford's trailing-12-month dividend yield is around 4.5%, while Pfizer's is around 6.9%. 10 stocks we like better than Ford Motor Company › Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream o ...

Energy Transfer LP (NYSE:ET) is one of the top cheap stocks under $20 to buy now. Morgan Stanley analyst Robert Kad reiterated a Hold rating on Energy Transfer LP (NYSE:ET) on December 23 and set a price target of $19.00. Why Energy Transfer (ET) Continues to Shine as a Promising Dividend Stock In a separate development, Energy Transfer LP (NYSE:ET) announced on December 18 growth in the transportation capacity of the Transwestern Pipeline’s planned Desert Southwest expansion project in order to meet ris ...

2025 is now drawing to a close, and U.S. stocks are set to deliver double-digit returns for the third consecutive year. It was a volatile year for the automotive industry, which battled the steep tariffs that President Donald Trump imposed on imports of cars and auto parts. The electric vehicle (EV) industry also faced a setback after the tax credit was withdrawn. Looking at the price action, General Motors (GM) is outperforming other auto stocks by a wide margin this year. Ford (F), too, is up 34% for t ...

Key Points The S&P 500 index has a tiny 1.1% yield, but this consumer staples icon is offering 2.9%. Coke has increased its dividend annually for over 50 years, making the company a Dividend King. The core business is performing well and tends to be resilient through the business cycle. 10 stocks we like better than Coca-Cola › Buying and holding a stock "forever" is a big commitment, and it shouldn't be taken lightly. If you are focused on owning for the long term like that, you need to select ...

Key Points Kraft Heinz's dividend yield is about 6.6% after the stock's pullback. Free cash flow has been running well above its dividend payments. Shares trade at just eight times trailing-12-month free cash flow. 10 stocks we like better than Kraft Heinz › Kraft Heinz's (NASDAQ: KHC) 6.6% dividend yield can make a significant difference in a portfolio for dividend investors seeking income. Of course, many investors are skeptical of high dividend yields -- and for good reason: high dividend yield ...

This insurance company's stock has been public for over 35 years, yet it's often overlooked by investors.Although it may have "old" in its name, dividend payouts from Old Republic International (ORI 0.01%) consistently reach new highs. Over the past four fiscal quarters, the insurance company has paid out $1.16 per share in dividends for investors, a 9.4% increase from the previous four-quarter period. And just recently, the insurer declared a special dividend of $2.50 per share set to pay out on Jan. 14, 2 ...

Investors looking for a top dividend stock in the financial sector may consider Franklin Resources (BEN). Franklin Resources — more widely known as Franklin Templeton — is a global financial firm offering a diverse range of products, including exchange traded funds, mutual funds, and fixed-income and customized investment strategies. With $1.66 trillion in assets under management, Franklin Templeton is a… ...

Abbott Laboratories (ABT), the global healthcare titan, announced on Dec. 22 that the U.S. Food and Drug Administration (FDA) has approved its Volt™ PFA System for treating atrial fibrillation (AFib). Abbott will soon begin commercial PFA procedures in the U.S. and continue expanding European sites, building on Volt’s CE Mark approval earlier this year and accelerating global market penetration. AFib presents a rapidly growing clinical and economic burden. Around 12 million Americans aged over 65 current ...

Core Viewpoint - UnitedHealth Group has faced significant challenges in 2025, with a year-to-date share decline of approximately 35%, marking its worst annual performance since 2008 [1] Financial Performance - The stock hit a 52-week low of around $235 in August but rebounded by roughly 46% to near $328 [2] - The company has lowered its earnings guidance for 2025 from an initial $29.50-30 per share to around $16.25 by the end of Q3 due to unexpectedly high medical costs in its Medicare Advantage business [3] - Revenue growth of 12% was reported in Q3, but profitability metrics declined, maintaining investor caution [5] Operational Challenges - The stock decline was influenced by high medical care ratios, reaching around 89%, and leadership changes, including the resignation of CEO Andrew Witty [3][4] - Ongoing investigations by the Justice Department into Medicare billing practices have added to the pressures faced by the company [4] Dividend and Cash Flow - UnitedHealth serves over 50 million consumers, with a year-over-year growth of nearly 800,000 members, generating trailing 12-month free cash flow exceeding $17 billion [6] - The company has a strong dividend track record, increasing payouts at double-digit rates over the past decade, with a current annual dividend of $8.84 per share [7] - With a payout ratio near 45%, the dividend is well-supported by earnings and cash flows, allowing for sustained growth [8] Valuation and Market Outlook - UnitedHealth trades at a trailing P/E of about 17.8, below historical averages, indicating potential investment opportunities [9] - Analysts maintain a consensus "Buy" rating with average price targets around $408 per share, suggesting over 20% upside [10] - An expected increase in Medicare reimbursements by up to 5% in 2026 and an aging population could lead to total returns of 15% to 20% in 2026 through dividend growth and stock appreciation [10] Investment Thesis - Despite the challenges faced in 2025, UnitedHealth's large membership base, strong cash generation, and conservative payout ratio position it favorably for future gains [12]

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...